RJS Biologics Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $225K
Latest Deal Amount
  • Investors
  • 2

RJS Biologics General Information

Description

Developer of novel cancer therapeutics and therapies designed to make cancer treatments more predictable. The company's services deliver beneficial therapeutics to patients suffering from cancer and other serious illnesses and also a novel drug conjugate approach that uses computationally designed affinity tags to drive therapeutic compounds into cancer cells and has a pipeline of conjugated anti-cancer compounds with payloads specific to a variety of clinically-relevant targets including kinase inhibitors, enzyme inhibitors and cell cycle inhibitors, enabling patients to get proper treatment for cancer without any side effect.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Delivery
Other Industries
Other Healthcare Services
Primary Office
  • 819 North 49th Street
  • Suite 307
  • Seattle, WA 98103
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

RJS Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 01-Jan-2017 $225K Completed Generating Revenue
2. Grant 11-Mar-2013 00000 Completed Generating Revenue
1. Equity Crowdfunding $750K Completed Generating Revenue
To view RJS Biologics’s complete valuation and funding history, request access »

RJS Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel cancer therapeutics and therapies designed to make cancer treatments more predictable. The company's
Drug Delivery
Seattle, WA
8 As of 2015
0000000000

00000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt m
0000 00000000
Tokyo, Japan
0 As of 0000
000.00
0000000000 0 000.00

00000 00

liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000000000000
Vancouver, Canada
0 As of 0000
00.00
0000000000 0 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RJS Biologics Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anaeropharma Science Venture Capital-Backed Tokyo, Japan 0 000.00 0000000000 0 000.00
00000 000000000 Venture Capital-Backed Vancouver, Canada 0 00.00 0000000000 0 00.00
00000 000000000000 Formerly VC-backed Philadelphia, PA 000 00000 000000&0 00000
00000000 Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 21 competitors. Get the full list »

RJS Biologics Executive Team (2)

Name Title Board Seat Contact Info
Stephen Mccraith Founder, President & Chief Executive Officer
Dwight Baker Chief Scientific Officer
To view RJS Biologics’s complete executive team members history, request access »

RJS Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RJS Biologics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Science Foundation Government 000 0000 000000 0
Life Sciences Discovery Fund Government 000 0000 000000 0
To view RJS Biologics’s complete investors history, request access »